L. Kirwan

Cystic Fibrosis Ireland — Ireland

Medicine · Health Sciences

22h-index2.9kcitations92works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cystic Fibrosis Research Advances(43), Ecology and Vegetation Dynamics Studies(22), Pediatric health and respiratory diseases(17), Breastfeeding Practices and Influences(8), Agronomic Practices and Intercropping Systems(8)

Publications92 total

Impact of two years of treatment with Elexacaftor/Tezacaftor/Ivacaftor on longitudinal changes in structural lung disease in people with Cystic Fibrosis – Results from the RECOVER trial
Annals of the American Thoracic Society·2026Open Access
105 Elexacaftor/Tezacaftor/Ivacaftor is associated with improvements in mucus plugging, air trapping and bronchial thickening but not bronchial widening in people with CF aged 12 years and older
Journal of Cystic Fibrosis·2025
P2.06.82 Cell Free DNA Dynamics in Exhaled Breath Condensate to Predict Outcomes to Immune Checkpoint Inhibition in Advanced NSCLC
Journal of Thoracic Oncology·2025
597 Changes in fecal microbiome and relationships with gut inflammation and abdominal symptoms over 6 months of treatment with elexacaftor/ tezacaftor/ivacaftor in people with CF – results from RECOVER
Journal of Cystic Fibrosis·2025· 1 cited
Late Breaking Abstract - Targeting senescence to reduce inflammation in alpha-1 antitrypsin deficiency (AATD)
2025
P387 Ensuring Excellence: The Data Quality Programme of the cystic fibrosis Registry of Ireland
Journal of Cystic Fibrosis·2025
P386 Health outcomes for PwCF switching from a CFTR modulator therapy (CFTRm) to elexaftor/tezacaftor/ivacaftor (ETI) compared with those starting on ETI naively. A study using Irish registry data
Journal of Cystic Fibrosis·2025
EPS2.07Assessment of the impact of the new born screening programme on growth and Pseudomonas aeruginosa infection in children with cystic fibrosis in Ireland: the Irish Comparative Outcomes Study (ICOS)
Journal of Cystic Fibrosis·2025
WS19.03 Improvements in structural lung disease over 24 months in children with CF aged 6-11 on elexacaftor/tezacaftor/ivacaftor (ETI) – interim analysis using automated LungQ scoring
Journal of Cystic Fibrosis·2025
Caries in a cohort of adults with cystic fibrosis: a cross-sectional study
BDJ·2025Open Access
Real-world improvement in ultra-low-dose thoracic computed tomography scores, systemic inflammatory markers and patient-reported outcome measures after elexacaftor/tezacaftor/ivacaftor treatment
ERJ Open Research·2024· 3 citedOpen Access
Random subsamples of animal populations can reveal intrinsic differences in sociality with key implications in ecology, conservation and disease transmission
2024Open Access
P2.11A.04 Exhaled Breath Biomarkers of Response to Immunotherapy in Advanced Non-Small Lung Cancer
Journal of Thoracic Oncology·2024
142 Clinical outcomes after 2 years of treatment with elexacaftor/tezacaftor/ivacaftor in children aged 6 to −11 with cystic fibrosis—The RECOVER Study
Journal of Cystic Fibrosis·2024
146 Liver disease outcomes in people with cystic fibrosis after 2 years of elexacaftor/tezacaftor/ivacaftor—results from the RECOVER trial
Journal of Cystic Fibrosis·2024
Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study
Journal of Cystic Fibrosis·2024· 4 citedOpen Access
EPS4.02 Exploring barriers to treatment adherence in people with cystic fibrosis: insights from the RECOVER study at 24 months
Journal of Cystic Fibrosis·2024
P124 Assessment of the impact of the newborn screening programme on lung function in children with cystic fibrosis in Ireland: The Irish Comparative Outcomes Study (ICOS)
Journal of Cystic Fibrosis·2024
EPS6.04 Getting ready for the storm: what cardiovascular disease metrics do national cystic fibrosis registries currently collect?
Journal of Cystic Fibrosis·2024
EPS4.01 Impact of 18 months of treatment with elexacaftor/tezacaftor/ivacaftor on clinical outcomes in children aged 6–11 with CF – the RECOVER study
Journal of Cystic Fibrosis·2024
page 1 of 5Next →

Frequent Co-authors

John A. Finn(22), John Connolly(19), Caroline Brophy(16), Maria‐Teresa Sebastià(15), A. Lüscher(15), R. P. Collins(10), C. Porqueddu(9), Á. Helgadóttir(9), B. Elnazir(9), D. Cox(8), Barry Linnane(8), B. E. Frankow‐Lindberg(7), Olivier Huguenin‐Elie(7), Paul McNally(7), Jane C. Davies(7), Barry J. Plant(7), O. H. Baadshaug(6), Alistair Black(6), A. Elgersma(6), M. Fothergill(6)